clinical trial · NCT06711640
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
USWM, LLC (dba US WorldMeds)·phase1·withdrawn
Opioid Withdrawal (Disorder)Opioid Use DisorderLUCEMYRA (lofexidine) tablets
brief summary
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to \<18 years old abruptly discontinuing opioid use.
started
Jun 1, 2025
primary completion
Jan 1, 2026
completion
Feb 1, 2026
last updated
Aug 1, 2025
detailed description
This is a Phase 1, Open-label, PK, safety, and tolerability study of LUCEMYRA in adolescents aged ≥12 to \<18 years abruptly discontinuing opioid use. The objectives of the study are to evaluate the PK parameters, as well as safety and tolerability. The effectiveness of LUCEMYRA on the signs and symptoms of acute opioid withdrawal will also be evaluated.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol